Capricor Therapeutics (CAPR) versus Its Rivals Critical Contrast
Capricor Therapeutics (NASDAQ: CAPR) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Capricor Therapeutics to similar businesses based on the strength of its earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and risk.
Earnings & Valuation
This table compares Capricor Therapeutics and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Capricor Therapeutics||$4.00 million||-$18.80 million||-2.68|
|Capricor Therapeutics Competitors||$284.28 million||$34.29 million||74.05|
Risk and Volatility
Capricor Therapeutics has a beta of -2.99, indicating that its stock price is 399% less volatile than the S&P 500. Comparatively, Capricor Therapeutics’ peers have a beta of 8.49, indicating that their average stock price is 749% more volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Capricor Therapeutics and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Capricor Therapeutics Competitors||852||3200||11603||231||2.71|
Capricor Therapeutics currently has a consensus price target of $4.33, suggesting a potential upside of 144.35%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 43.84%. Given Capricor Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Capricor Therapeutics is more favorable than its peers.
Institutional & Insider Ownership
4.6% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 28.5% of Capricor Therapeutics shares are held by insiders. Comparatively, 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Capricor Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Capricor Therapeutics Competitors||-5,312.21%||-433.82%||-39.43%|
About Capricor Therapeutics
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.